CTI BioPharma Corp (NASDAQ:CTIC) reported financial results for the fourth quarter and full year ended December 31, 2015. “While we were disappointed and surprised …
Red flags were thrown up by analysts today regarding the prospects of biotech company CTI BioPharma Corp (NASDAQ:CTIC) and solar-leasing giant SolarCity Corp (NASDAQ:SCTY). The analysts …
CTI BioPharma Corp (NASDAQ:CTIC) provided an update regarding the clinical studies being conducted under the Company’s Investigational New Drug (“IND”) application for pacritinib. Following …
Piper Jaffray’s healthcare analyst Charles Duncan is weighing in today on biotech companies CTI BioPharma Corp (NASDAQ:CTIC) and BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), as shares …
CTI BioPharma Corp (NASDAQ:CTIC) announced that the Company received written communication from the U.S.
CTI BioPharma Corp (NASDAQ:CTIC) announced positive progress of its lead clinical program in addition to several key business priorities for 2016. “After a productive 2015, …
CTI BioPharma Corp. (NASDAQ:CTIC) and Baxalta Inc(NYSE:BXLT) announced the completion of the rolling submission of the New Drug Application (NDA) to theU.
CTI BioPharma Corp (NASDAQ:CTIC) announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones …
CTI BioPharma Corp CTI BioPharma Corp (NASDAQ:CTIC) shares are tumbling 16.24% to $0.
CTI BioPharma Corp (NASDAQ:CTIC) announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-2 …
